IP Library Granted Patent US 9,315,577
Granted Patent B2
US 9,315,577 · App. 12/990,137 · Granted Apr 19, 2016

Anti-hepcidin antibodies and methods of use

Inventors: Ian Foltz (Burnaby, CA); Michael Gallo (North Vancouver, CA); Keegan Cooke (Ventura, CA); Randal R. Ketchem (Snohomish, WA); Christopher Mehlin (Seattle, WA)
Assignee: AMGEN INC.
C07K16/26A61K38/1816A61K39/3955A61K2039/505C07K2317/21C07K2317/56C07K2317/565C07K2317/76C07K2317/77C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,315,577
App. No.
12/990,137
Granted
Apr 19, 2016
Kind
B2
Abstract

The invention relates to monoclonal antibodies that bind hepcidin and methods of making and using such antibodies. Also provided are methods of treating hepcidin-related disorders.

Claims (11)

1. An isolated antibody comprising SEQ ID NOs: 334-339 wherein the antibody binds to human hepcidin of SEQ ID NO: 9 with an affinity K D of less than about 10 −8 M and which exhibits at least one of the properties selected from the group consisting of:

(a) at least about a 50-fold higher K D at a pH of about 5.5 compared to its K D for said hepcidin at a pH of about 7.4;

(b) at least about a 5-fold faster clearance of said hepcidin compared to antibody 1S1 having the heavy chain variable region of SEQ ID NO: 202 and the light chain variable region of SEQ ID NO: 128; and

(c) an off rate of about 6×10 −2 s −1 or higher at about pH 5.5.

2. An isolated antibody comprising the amino acid sequence SEQ ID NOs: 334-339 that binds to human hepcidin of SEQ ID NO: 9, with an affinity K D of at least 10 −8 M and said antibody has at least about a 50-fold higher K D at about pH 5.5 compared to its K D for said hepcidin at about pH 7.4 or said antibody has an off rate of about 6×10 −2 s −1 or higher at about pH 5.5, wherein said antibody is obtained by:

(a) replacing an amino acid in the heavy or light chain of said antibody with a histidine;

(b) screening the antibody obtained in (a) for differential pH binding;

(c) replacing another amino acid in the heavy or light chain of said antibody with a histidine; and

(d) screening said antibody for having at least one of the properties selected from the group consisting of:

(i) at least about 50-fold higher K D at about pH 5.5 compared to its K D for said hepcidin at about pH 7.4; and

(ii) an off rate of about 6×10 −2 s −1 or higher at about pH 5.5.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2011
From: FOLTZ, IAN; GALLO, MICHAEL; COOKE, KEEGAN; KETCHEM, RANDAL R.; MEHLIN, CHRISTOPHER
To: AMGEN INC.
Reel/Frame 025813/0147 →
Continuity (2)
Provisional Application 61049687 · May 1, 2008
Related Publication 20110150888A1 · Jun 23, 2011